The Mood Disorders Research Program (MDRP) has performed numerous important studies of Dysthymic Disorder and other types of Depression. The MDRP is now part of the Depression Evaluation Service, a world-renowned research clinic of the New York State Psychiatric Institute and the Columbia University Department of Psychiatry. In its previous locations at Beth Israel Medical Center and St. Luke's Roosevelt Hospital, the MDRP performed the world's first double-blind-placebo controlled study of an SSRI medication in "pure dysthymia"--that is, Dysthymic Disorder without a superimposed episode of Major Depression. In 2007 the MDRP moved to its current location in midtown Manhattan, at 1775 Broadway (3 Columbus Circle). Research participants can be seen either at our midtown (57th St.) or uptown (Riverside Drive at 165th St.) locations.
The program has also been a site for other important clinical studies, including the largest medication study to date on DD (Zoloft vs. imipramine vs. placebo), and a groundbreaking study of St. John's Wort in moderate to severe depression, which was published in the Journal of the American Medical Association. The MDRP has also participated in studies of numerous new antidepressant medications, including citalopram (Celexa), bupropion extended release (Wellbutrin XL), duloxetine (Cymbalta), and lamotrigine (Lamictal). Other studies have focused on characterizing the most common symptoms of DD, on developing better scales to measure the response to treatment, and on developing a combined psychotherapy-medication approach for the treatment of DD.
IF YOU LIVE IN THE NEW YORK AREA
and would like information about participating in our studies, please contact us at: 646-774-8000
Department of Psychiatry
of Chronic Depression
Mood Disorders Research Program/
Depression Evaluation Service
1775 Broadway , Suite #1403 (57th St)
New York, NY 10019